Trazol Plus

Trazol Plus

- TRAZOL® Plus : is a combination of Diloxanide  furoate; 
 a luminal amoebicide and Metronidazole; a potent tissue 
 amoebicide. They have a synergistic and comprehensive 
 activity against all kinds of  amoebiasis either vegetative or 
 cystic, and both intestinal or  extra-intestinal amoebiasis  
 without need for addition drug.
-Metronidazole is a 5-nitroimidazole derivative with activity  
 against obligate anaerobic microorganism, both bacteria and 
 protozoa. 
-Metronidazole is widely distributed, it appears in most body 
 tissues and fluids including bile, bone, breast milk, cerebral 
 abscesses, CSF,  liver and liver  abscesses, saliva, seminal 
 fluids and vaginal secretions and achieves concentration 
 similar to those in plasma. 
-The mechanism of action of metronidazole is thought to 
 involve  interference with DNA by a metabolite in which the 
 nitro group of Metronidazole has been reduced. 
- Because of rapid absorption of Metronidazole, it is probably 
 less effective against parasites in the bowel lumen therefore it 
 is used in conjunction  with a luminal amobicide diloxanide 
 furoate in the treatment of invasive  amobiasis. 
- Diloxanide furoate is a dichloroacetamide derivate, it is 
 a luminal amobicide acting principally in bowel lumen.
- Diloxanide furoate is suitable for eradication of the parasites 
 in amoeba and giardia cyst passers. 
 

-Each film coated tablet of TRAZOL® Plus contains :
  Diloxanide furoate      250  mg
  Metronidazole            200  mg
-Each 5 ml of TRAZOL® Plus oral suspension contains :
  Diloxanide  furoate    100  mg  
  Metronidazole           125  mg (as Metronidazole benzoate)
  

- Hypersensitivity to any component of  TRAZOL® Plus .  
 

- Metronidazole increases blood levels of warfarin and other oral 
  coumarin anticoagulants, resulting in prolongation of 
  prothrombin time.         
- Concomitant use of Alcohol with TRAZOL® Plus may lead 
  to disulfiram like reaction.
- Barbiturates and phenytoin increase the TRAZOL® Plus
  metabolism so  may diminish the antimicrobial effectiveness 
  of  Metronidazole (may be need to increase the dose). 

- TRAZOL® Plus should be avoided during the first trimester 
  of pregnancy. 
- TRAZOL® Plus should be avoided during lactation, 
  otherwise breast  feeding should be stopped.

- Flatulence and gastrointestinal disturbances especially: nausea, 
  unpleasant metallic taste, vomiting , diarrhea  or constipation.    - Weakness, dizziness, ataxia, headache, drowsiness, skin rash, 
   urticaria, and pruritus. 
- In high doses or prolonged treatment with TRAZOL® Plus,  
  peripheral  neuropathy and epileptic form seizures have been 
  associated.

  TRAZOL® Plus should be used with cautions in the following 
  cases.
- Doses should be reduced in elderly and in patients with severe 
  liver or renal impairment.  
- Patients with a history of blood dyscrasia, because the drug 
  can cause leukopenia.        
- Administration with caution in patients with CNS disease.               
- If therapy with TRAZOL® Plus exceeds 10 days, regular 
  clinical and  laboratory monitoring is advised. 

- TRAZOL® Plus tablets:
  Blisters of 10 Tablets, pack of 2 blisters.
- TRAZOL® Plus oral suspension: 
  Bottle of 100 ml. 

- Store in a dry place at a temperature below 25 °C.